



Supplementary Fig. 4. Correlation of diacylglycerol O-acyltransferase 2 (DGAT2) and clinical factors. (A) Expression level of *DGAT2* based on etiologies. (B) *DGAT2* expression level based on the gender in hepatocellular carcinoma patients. (C) Correlation of *DGAT2* and body mass index (BMI) from The Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC) cohorts. Calculated with linear regression. (D) Expression level of *DGAT2* based on liver pathology state in GSE193084. (E) Expression level of *DGAT2* based on fibrosis score of patients in GSE193084. Data represent mean \pm standard deviation. NAFLD, non-alcoholic fatty liver disease; NS, not significant. ^a $P < 0.05$, ^b $P < 0.01$, ^c $P < 0.0001$; two-tailed Mann-Whitney *U* test.